TY - JOUR T1 - Autoantibodies Detected in MIS-C Patients due to Administration of Intravenous Immunoglobulin JF - medRxiv DO - 10.1101/2021.11.03.21265769 SP - 2021.11.03.21265769 AU - Peter D. Burbelo AU - Riccardo Castagnoli AU - Chisato Shimizu AU - Ottavia M. Delmonte AU - Kerry Dobbs AU - Valentina Discepolo AU - Andrea Lo Vecchio AU - Alfredo Guarino AU - Francesco Licciardi AU - Ugo Ramenghi AU - Emma Rey AU - Maria Cecilia Vial AU - Gian Luigi Marseglia AU - Amelia Licari AU - Daniela Montagna AU - Camillo Rossi AU - Gina A. Montealegre Sanchez AU - Karyl Barron AU - Blake M. Warner AU - John A. Chiorini AU - Yazmin Espinosa AU - Loreani Noguera AU - Lesia Dropulic AU - Meng Truong AU - Dana Gerstbacher AU - Sayonara Mató AU - John Kanegaye AU - Adriana H. Tremoulet AU - Pediatric Emergency Medicine Kawasaki Group AU - Eli M. Eisenstein AU - Helen C. Su AU - Luisa Imberti AU - Maria Cecilia Poli AU - Jane C. Burns AU - Luigi D. Notarangelo AU - Jeffrey I. Cohen Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/04/2021.11.03.21265769.abstract N2 - The autoantibody profile associated with known autoimmune diseases in patients with COVID-19 or multisystem inflammatory syndrome in children (MIS-C) remains poorly defined. Here we show that adults with COVID-19 had a moderate prevalence of autoantibodies against the lung antigen KCNRG, and SLE-associated Smith autoantigen. Children with COVID-19 rarely had autoantibodies; one of 59 children had GAD65 autoantibodies associated with acute insulin-dependent diabetes. While autoantibodies associated with SLE/Sjögren’s syndrome (Ro52, Ro60, and La) and/or autoimmune gastritis (gastric ATPase) were detected in 74% (40/54) of MIS-C patients, further analysis of these patients and of children with Kawasaki disease (KD), showed that the administration of intravenous immunoglobulin (IVIG) was largely responsible for detection of these autoantibodies in both groups of patients. Monitoring in vivo decay of the autoantibodies in MIS-C children showed that the IVIG-derived Ro52, Ro60, and La autoantibodies declined to undetectable levels by 45-60 days, but gastric ATPase autoantibodies declined more slowly requiring >100 days until undetectable. Together these findings demonstrate that administration of high-dose IVIG is responsible for the detection of several autoantibodies in MIS-C and KD. Further studies are needed to investigate autoantibody production in MIS-C patients, independently from IVIG administration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Intramural Research Programs of NIDCR and NIAID of the National Institutes of Health and Regione Lombardia (project -Immune response in patients with COVID-19 and co-morbidities), FONDECYT 11181222 (M.C.P.), ANID-COVID19 0999 (M.C.V.) and NIH 3R01HL140898-03S1 and NICHD 1R61HD105590 (J.C.B and A.H.T). We thank the NIAID Office of Cyber Infrastructure and Computational Biology, Bioinformatics and Computational Biosciences Branch (Contract HHSN316201300006W/HHSN27200002 to MSC, Inc) and Operations Engineering Branch for developing the HGRepo system to enable streamlined access to the data and the NCI Advanced Biomedical Computational Science (ABCS) for data transformation support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Deidentified plasma or serum samples were obtained from patients with COVID-19 or control subjects from multiple sites under an NIH IRB exemption after local IRB approval: Brescia, Italy Comitato Etico Provinciale (NP 4000 and NP 4408); Pavia, Italy (Comitato Etico Pavia Prot. 20200037677); Turin, Italy (Comitato Etico Interaziendale A.O.U. Citta della Salute e della Scienza di Torino, Protocol: 00282/2020); Naples, Italy (Ethics Committee of the University of Naples Federico II, Protocol: 158/20); Chile (Comite Etico Cientifico Facultad de Medicina Clinica Alemana Universidad del Desarrollo, Santiago, Chile, Protocol: 2020-41); and Israel (Hadassah Medical Organization Institutional Review Board (IRB) for studies involving human subjects, Protocol: HMO-235-20). Additional MIS-C patients were enrolled from other sources including Stanford, California and Portland, Oregon, after written informed consent to NIH IRB-approved research protocols (NIH Protocols l1-1-0109, 18-I-0041 and 18-I-0128). Sera from children with KD or acute febrile illnesses were obtained at the University of California, San Diego under IRB approved protocols (UCSD #140220). All patients and parents gave written informed consent and assent as appropriate. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. ER -